Binding of RHOA G17V to p300 enhances its HAT activity: a new mechanism of epigenetic deregulation in TFH lymphoma

By D. Vallois, Mélanie Juilland, Kalliopi Ioannidou, F. Lemonnier, E. Missiaglia, Bettina Bisig, Margot Thome, L. D. de Leval. Blood Advances, 2025

5,541 citations recorded by the source corpus.

Key Points • RHOA G17V enhances CD3/CD28-induced NFAT transcriptional activity by binding p300 and enhancing its histone acetyltransferase activity.• RHOA G17V, a mutation altering the function of a signaling molecule, has epigenetics effects.

Subfields: Dermatology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/15363add478f14d594d1c0b7f7536ac93908f3e6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

  1. Waltraud X. Schulze

Citations in the corpus